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Biomarkers: The Clues to Genetic Susceptibility
There are approximately 500,000 cancer-
related deaths annually in the United
States. Scientists believe as that many as
80% of those deaths could be prevented
due to the fact that most malignancies are a
result ofexternal factors rather than inher-
ent biological conditions. With recent
advances in molecular biology, a new field
that combines highly sensitive and specific
techniques for detecting early damage asso-
ciated with cancer has emerged. By com-
bining knowledge about external factors
related to lifestyle and environmental or
occupational exposure to chemicals with
knowledge ofhow genetic differences cause
variations in human responses to environ-
mental pollutants, scientists are developing
a better understanding ofquestions such as
why some smokers get cancer but others do
not, why certain groups of people have a
higher incidence ofcancer after exposure to
a toxicant and others do not, and why cer-
tain women are more prone to develop
breast cancer than others. Scientists using
biomarkers ofsusceptibility will be able to
identify risks and prevent adverse health
effects through prevention and interven-
tion strategies.
The Clues at Hand
In 1987 the National Research Council of
the National Academy of Sciences defined
biological markers as "indicators signaling
events in biological systems or samples"
and classified them into three types: mark-
ers of exposure, markers of effect, and
markers of susceptibility. Each of these
types of biomarkers has specific and rele-
vant application to the assessment, and
potentially ensurance, of environmental
health.
Exposure. External exposure is the
amount of a xenobiotic substance (outside
living systems) to which a person is subject-
ed, whereas internal dose is the amount ofa
substance absorbed into the body. Markers
ofexposure indicate the presence ofa xeno-
biotic compound and its interactions within
an organism. In addition to assessing expo-
sure by mathematical modeling and ambi-
ent monitoring by chemical or physical
analysis of food, air, water, and soil, expo-
sure is also assessed by measuring xenobi-
otics in blood, urine, saliva, cerebrospinal
fluid, and other biological samples.
Markers of exposure offer a more accurate
means of estimating exposure than mathe-
matical modeling or analyzing environmen-
tal samples.
Effect. Biological markers of effect
indicate the presence of disease, early pre-
cursors ofdisease, or events peripheral to a
disease process that may predict the devel-
opment of impaired health. Markers of
effect represent points on a continuum of
health impairment and may be measured
qualitatively or quantitatively. Early
responses to exposure may include changes
in the function oftarget tissues or respons-
es in organs or tissues such as chromosomal
damage, mutations of critical target genes,
or altered hormone status.
Susceptibility. A third kind of biologi-
cal markers indicates differences in individ-
uals or populations that affect the body's
response to environmental agents. Markers
of susceptibility may include genetic char-
acteristics, preexisting disease that results in
an increase in the amount of agent
absorbed or the target tissue responses, dif-
ferences in metabolism, variations in
immunoglobulin levels, or the capacity of
an organ to recover from environmental
insult. Markers ofsusceptibility are partic-
ularly relevant to determining inherited
predisposition to risk of adverse health
effects as a result of exposure to environ-
mental chemicals.
Continuum of change. Gray arrows indicate sequence of events from exposure to clinical disease. Yellow
lines indicate the influence ofindividual susceptibility and otherfactors on steps ofthe disease process.
Environmental Exposure
People living in industrialized countries are
exposed extensively to chemicals that cause
mutations, cancer, and birth defects. For
example, more than 700 organic chemicals
have been identified in the drinking water
supply in the United States; 40 are possible
carcinogens. There are at least 320 toxic
industrial chemicals released into ambient
air; 60 are possible carcinogens. Ofapprox-
imately 380 pesticides manufactured in
this country that are applied to food prod-
ucts, 66 have been identified as carcino-
genic or potentially cancer causing.
Categories of common substances that
could increase carcinogenic risk include
aromatic amines, nitrosamines, chlorinated
hydrocarbons, polycyclic aromatics, radio-
nuclides, metal dusts, molds, and steroid
hormones.
Exposure to aromatic amines such as
benzidine and 2-naphthylamine used in
dye making, rubber manufacture, and ana-
lytical laboratories may cause bladder can-
cer. Nitrosamines are used as additives for
food preservation, in rubber manufacture,
and are present in tobacco smoke.
Chlorinated hydrocarbons include vinyl
chloride used in the manufacture of
polyvinylchloride (PVC) and organochlo-
rine insecticides such as aldrin, dieldrin,
and DDT. Polycyclic aromatic hydrocar-
bons (PAHs) are products of tobacco
smoke and combustion of fossil fuels.
Radionuclides such as strontium-90 and
plutonium-239 are used as medical and
scientific diagnostics, used by the military,
and used as fuel in nuclear power stations.
There are various uses for different metal
dusts such as arsenic, used in pesticides and
drug manufacture, beryllium, used in the
production oflightweight alloys and rocket
fuel, and chromates, used in paint pig-
ments. Food may be contaminated by
molds that produce toxic compounds. The
infestation of rye by ergot (the fungus
Ciavicepspurpurea) causes ergotism, a dis-
ease characterized by severe mental disor-
der and hallucination. Other fungal prod-
ucts, such as aflatoxins produced by the
mold Aspergillus that grows on peanuts,
corn, rice, and sorghum, are known car-
cinogens. An example of a carcinogenic
steroid hormone is diethylstilbestrol, which
is added to animal feed and used as a
"morning after pill." The question for all
ofthese substances is: How do we know if
a person is likely to develop disease or
incur a heritable genetic mutation that
could cause problems, such as learning dis-
abilities or high risk for cancer, in future
generations as a result ofexposure?
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The underlying principle of susceptibility
markers is the interindividual differences
that confer sensitivity or resistance to envi-
ronmentally induced disease. The first type
ofsusceptibility marker is based on the fact
that most chemicals are altered by
enzymes, and these alterations may in-
crease or decrease the ability of a chemical
to interact with DNA, RNA, or proteins.
The balance between enzymes that detoxi-
fy or enhance the toxicity ofchemicals dif-
fers among individuals and ethnic groups.
These differences often are inherited and
can lead to pronounced differences in a
person's sensitivity to the effects ofchemi-
cal exposure.
A second type ofsusceptibility marker
reflects genetic differences in the capacity
of cells to repair DNA damage caused by
environmental insult. People deficient in
DNA repair genes may exhibit more DNA
damage manifest as DNA adducts; alter-
ations in chromosome number; structural
modifications such as chromosome breaks,
rearrangements, and exchanges; micronu-
clei, which are fragments ofnuclear materi-
al left in the cytoplasm after replication;
activated oncogenes and their protein
products; and much higher incidences of
cancer.
A third type ofsusceptibility marker is
preexisting inherited genetic defects that
increase the risk ofcancer. Cancer is gener-
ally understood to be a multistage process,
requiring several genetic alterations or
mutations to produce a clinically detecta-
ble tumor. If a person has inherited one or
more of the necessary genetic alterations,
fewer steps are needed for a chemical to
cause cancer, putting this person at a
greater risk.
Enzyme metabolism. There is consid-
erable variation among humans in the
production of enzymes that either
activate formation of electrophilic
metabolites that covalently bind to DNA
or catalyze detoxification of chemical
carcinogens. A large number of enzymes
involved in regulation ofmetabolic path-
ways, many of which originally evolved
in humans to handle naturally occurring
toxicants, play an important role in
detoxifying compounds humans are
exposed to today as a result of environ-
mental pollution. Within each group of
enzymes, there are many forms that have
evolved to metabolize different chemi-
cals. For example, there are approximate-
ly 40 cytochrome P450 enzymes that
evolved from a common ancestral
cytochrome gene, estimated to be 2000
million years old. Each ofthe 40 forms is
composed ofvariants that have different












A kink in the chain. There are at least three classes of inherited susceptibility to cancer with great
genetic variation among humans.
Recent findings by several research
groups including those at NIEHS, Duke
University Medical Center, and the
University of North Carolina at Chapel
Hill School ofMedicine illustrate that the
abilityofindividuals to metabolize carcino-
gens before damage occurs varies widely.
Researchers from the three groups collabo-
rated on an epidemiological study correlat-
ing exposure risk and genetic susceptibility
to bladder cancer. "There is large variation
in the human populations in how well
individuals are protected," says Douglas
Bell, an NIEHS researcher. "Some people
have a high ability to detoxify environmen-
tal chemicals and others do not."
The association between lung cancer
and smoking is well established, and there
is now evidence ofa link between smoking
and bladder cancer. In a study of bladder
cancer patients and control subjects, re-
searchers found that approximately halfof
all subjects inherit a gene that encodes for
glutathione S-transferase M1, an enzyme
that detoxifies environmental carcinogens
such as the PAHs in tobacco
smoke. Because the DNA
nucleotide sequence of the
GSTMI gene is known, it
was possible to use a molecu-
lar genetic technique known
as polymerase chain reaction
to rapidly screen patient
blood samples and deter-
mine whether a subject had
two copies of the gene, one
copy of the gene, or was
missing the gene. Individuals
who had at least one func-
tional copy of the GSTMJ
gene were less likely to Douglas Bell-
develop bladder cancer than protectedthe:
-N
sam
individuals without the gene. Individuals
who have two copies ofthe gene probably
have an even greater level of protection.
The findings show that genetic predisposi-
tion combined with environmental expo-
sure is an important factor in development
ofdisease.
Fred Kadlubar, a researcher at the
National Center for Toxicologic Research
studying biochemical pathways associated
with carcinogen-DNA adducts, has shown
how certain individuals may be susceptible
to some carcinogens and protected from
others. The enzyme acetyltransferase also
plays an important role in risk for bladder
cancer among smokers. Individuals who
are "slow acetylators" inherit two recessive
genes from their parents, and there is a
higher incidence of bladder cancer among
smokers of this genotype. Smokers who
have at least one dominant gene are fast
acetylators and have lower susceptibility to
bladder cancer. Further work also showed,
however, that fast acetylators had greater
susceptibility to colon and rectal cancer
when exposed to harmful
_ by-products of cigarette
Z smoking. In addition, other
behaviors, such as eating
well-done meat, also in-
crease cancer risk in these
individuals. Changes in
lifestyle, such as quitting
smoking or modifying diet,
may help reduce these risks.
Scientists and the public are
becoming increasingly aware
of how important diet can
be in the prevention ofdis-
ease, as researchers discover
lot everyone is that certain chemicals in
ie. foods are necessary for prop-
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er biochemical function of
metabolic pathways. Ac-
cording to Kadlubar,
"Enzymes that play a role
in detoxification are
induced by eating yellowN
and green vegetables."
Such foods contain induc-
ers of enzymes that pre-
vent formation ofthe car-
cinogen-DNA adducts
that lead to cancer, such as
vitamin C, which reduces
the rate of DNA damage
resulting from nitrates, Frederica Perere
and vitamin E, which is a may tell us who
free-radical scavenger and cancer.
prevents oxidative damage
to DNA.
Frederica Perera of theP Columbia
University School of Public Health is col-
s_
lis fil
, laborating with researchers
, from Sweden and Poland to
= study gene mutation and
E oncogene activation in relation
S to markers of exposure, effect,
and susceptibility. These stud-
ies show increased levels in
PAH-DNA adduct formation
and other biomarkers as a
result of environmental and
occupational exposure to
chemicals. PAHs emitted from
industrial and residential burn-
ing of coal are known to have
Biomarkers mutagenic and carcinogenic
likely to get activity. In a recent segment of
the study conducted in Silesia,
Poland, a heavily polluted city
with a high rate ofcancer and infant mor-
tality, multiple biomarkers such as carcino-
gen-DNA adducts, chromosomal aberra-
When DNA was first discovered, it i
of every word-er amino aid se(
tions, sister chromatid exchange, and acti-
vation of ras oncogenes were analyzed in
blood. PAH exposure from ambient air,
drinking water, and the food supply in
Silesia is 10-30 times higher than in most
Western countries. There were significant
increases in PAH-DNA adducts, aromat-
ic-DNA adducts, and chromosomal muta-
tions, as well as a doubling in rasoncogene
expression in environmentally exposed resi-
dents compared to control subjects who
lived in a rural, less polluted area.
Although there was a correlation
between exposure to PAHs and chromoso-
mal mutation, linking a specific environ-
mental exposure to induced genetic modifi-
cations relevant to cancer and reproduction
risks, some people were especially sensitive
and others were resistant. Therefore, the
Silesia population offers an opportunity to
determine if various susceptibility markers
can explain interindividual differences in
response to a given exposure level of an
environmental carcinogen. The study also
has relevance for other kinds ofexposures in
parts of the world where PAHs are a com-
mon pollutant, particularly those areas with
numerous coal-burning factories.
In another study conducted by Perera
and her colleagues, workers in an iron
foundry in Finland who were occupation-
ally exposed to PAHs had significantly
higher levels of carcinogen-DNA adducts
than controls. Fluctuations in carcino-
gen-DNA adducts, carcinogen-protein
adducts, gene mutation at the HPRTand
GPA loci, and chromosomal mutation are
being historically monitored. Lowered
PAH exposure due to improved industrial
hygiene and reduction ofindustrial output,
caused by an economic recession, has
resulted in a decrease in adduct levels. To
assess individual variation in susceptibility,
these workers are also being screened by
researchers at NIEHS for genetic traits that
govern metabolism and detoxification of
PAHs. A profile ofthe interrelationship of
environmental exposure with genetic or
acquired factors governing individual sus-
ceptibility to mutagenic and carcinogenic
effects is being charted. Said Perera, "These
findings suggest that adducts are not only
an environmentally relevant dosimeter but
that they may also indicate heightened risk
of cancer." George Lucier of NIEHS adds
that the results of this study "represent a
growing consensus that gene-environment
interactions must be better understood if
we are going to be able to accurately esti-
mate risks from exposure to environmental
agents." Ultimately, this approach will
enhance risk assessment, improve predic-
tion of individual health outcome, and
facilitate prevention.
DNA repair. In addition to signaling
exposure or susceptibility to a mutagenic
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agent, biomarkers also indicate inability to
repair damage. DNA has a network of
repair mechanisms to prevent injury and
maintain the integrity ofthe genetic mater-
ial that drives normal cellular and biologi-
cal processes. Under normal circumstances,
during replication ofDNA, repair enzymes
travel along the molecule and excise mis-
matches ofnucleotide base pairs or aberra-
tions in molecular structure, such as
adducts. When there is a deficiency in the
system of repair genes of an individual,
that person is predisposed to developing
cancer. Excision repair enzymes also pro-
vide backup protection for correcting
errors in the genetic code and architectural
distortions during replication. Just as
metabolic responses to chemical exposure
vary from one person to another, DNA
excision repair is highly variable among
individuals ofanypopulation.
The idea that recovery mechanisms
could repair damaged DNA was conceived
by Philip C. Hanawalt when he was a
graduate student in Richard Setlow's labo-
ratory at Yale University in the early
1960s. In subsequent years, Hanawalt has
been a leader in pioneering research to elu-
cidate the complicated system of
nucleotide-excision repair (NER). Many
agents, both endogenous and environmen-
tal, damage DNA. The recovery mecha-
nism has to be highly specific to ensure
that repair enzymes act only on damaged
DNA instead ofother DNA configurations
that occur during transcription (synthesis
of messenger RNA). Hanawalt has shown
that NER is linked to transcription. As
polymerase I, the transcription enzyme,
moves along a DNA strand
and approaches a lesion, it
pauses, and a multienzyme
complex recognizes and
binds the damaged portion
of DNA. The interaction
ofthe repair enzymes initi-
ates excision of the dam-
aged segment, then tran-
scription continues, and
the polymerase, using the
old DNA strand as a tem-
plate, generates a new piece
of DNA and replaces the
excised segment with the
correct nucleotide pairs, Philip Hanawalt
which are then bound to ery mechanisms
the DNA molecule. specific.
An example of an inherited disease
characterized by defective NER is xeroder-
ma pigmentosum, in which people are
highly sensitive to ultraviolet light and
have more than a 2000-fold increased risk
of skin cancer. By studying the genetic
sequences in xeroderma pigmentosum that
are involved in correcting UV sensitivity
and repairing the DNA, significant
It-I
;MU.
progress has recently been
made in cloning and charac-
terizing human NER genes.
Seven proteins have been
implicated in the early steps
of damage recognition and
nucleotide excision. It has
been shown that there is
preferential repair in tran-
scribed DNA strands, and
there is greater efficiency in
recognizing and repairing
adducts formed by different
chemicals within certain
nucleotide sequences.
Inherited susceptibility. Roger Wisema 1 1 1 * 1 * r ~~for the breast Although inheritance of a be availablewil
defective gene is a factor in a
small percentage of people who develop
cancer (less than 5%), susceptibility in
such individuals is many times greater in
people who carry a defective gene.
Inherited cancers provide an opportunity
to understand the genetic mechanisms of
mutagenesis.
Breast cancer has dramatically
increased in the last 50 years. It is estimat-
ed that 1 out of every 10 women will
develop breast cancer over the course of
her lifetime. The extent to which this
increase can be attributed to better detec-
tion versus diet or exposure to environ-
mental pollutants is not known. Mary
Claire King and colleagues at the
University of California at Berkeley have
discovered the region in the human
genome where the gene for inherited breast
cancer resides. This region, on the long
arm of chromosome 17, is composed of
approximately 400,000 nu-
cleotides; some code for pro-
I teins and others are genes.
Roger Wiseman of NIEHS is
,, one of many scientists trying
to identify the genes in this
region with the goal of find-
ing the gene for increased sus-
ceptibility to breast and ovari-
an cancer. Work on the gene,
named BRCAI, promises to
shed new light on the etiology
of breast cancer. Wiseman
says that "once the gene has
been found, it will be possible
DNA recov- to determine whether individ-
lst be highly uals have germline mutations
that would predispose them to
developing breast cancer."
It is already known that the genetic
alteration in the defective gene is confined
to one amino acid. One in 200 women
inherit a bad copy of the gene, and of
those, approximately 80% develop breast
or ovarian cancer. Even when an individual
inherits a defective copy ofthe gene, other




tumorigenesis. Environmen- _ tal agents may inactivate
genes that are important in
genetic control. According
to Wiseman, "The p53
tumor-suppressor gene has
been inactivated or deleted
in one-half to two-thirds of
all breast cancers."
Once the BRCA1 gene
has been identified and
cloned, it will provide valu-
able clues for unlocking the
mystery of the genetics of
breast and ovarian cancer. -A blood test With that knowledge, detec-
cer gene may tion, risk assessment, and
i a year. opportunities to develop
new therapies and examine a causative role
for environmental agents will be greatly
enhanced. Scientists believe this break-
through is imminent. Wiseman predicts
that "within the next year a blood test to
detect mutations in the gene will be a fairly
routine assay, depending on how big the
gene is and how many mutations are in it."
According to Wiseman, such an assay will
make it possible to identify high-risk indi-
viduals, develop better therapies for treat-
ing people with tumors who have a muta-
tion in the gene, and study what kinds of
environmental factors increase risks when a
woman has inherited a bad copy of the
gene.
For individuals with an inherited pre-
disposition to colon cancer, a disease that
threatens 1 in 200 Americans, these risk
identification and treatment possibilities
may come even sooner. On 3 December
1993, molecular biologists Richard
Kolodner of the Dana-Farber Cancer
Institute and Richard Fishel of the
University ofVermont announced the dis-
covery ofthe gene for inherited colon can-
cer, barely edging out a team from Johns
Hopkins University School of Medicine,
headed by Bert Vogelstein and Kenneth
W. Kinzler, who reported the same discov-
ery two weeks later in the journal Cell. "It
was like finding a misplaced comma in a
300-volume encyclopedia,"said Jeffrey
Trent, a researcher at the National Center
for Human Genome Research (NCGHR),
in an article announcing the discovery in
the New York Times.
Researchers expect to have a blood test
available to test for the gene, which is
blamed for the 15% of colon cancers esti-
mated to be inherited, as well as many
inherited cancers of the uterus and ovaries
in women, within six months.
Vogelstein has shown that colon cancer
generally requires the actions of half a
dozen or more oncogenes to initiate
tumors. The newly discovered gene,
(continuedonp.56)
Volume 102, Number 1, January 1994 53.Ev
Mapping the Human
Genome: A Status F
When the Human Geno
began in 1988, many skeptic
supporters, doubted that it C(
ambitious goals and wonc
results of such a program c
the enormous cost. Mappin
human genome-somewhei
billion base pairs-by the
year 2005 seemed an almost
impossible task, given the
technology available at the
time. Yet as the project
enters the fourth year Of its
initial five-year phase, ques-
tions about its validity have
faded and "advances in ge-
nome research have already
changed the way the re-
search is being done," says
Frances Collins, director of
the National Center for
Human Genome Researh
(NCHGR), prompting the
release of a new set ofgoals




effort to answer questions
about genetic components
of illness and disease. By
mapping all 24 chromo-
somes of the human
genome, scientists hope to
be able to isolate genes
responsible for particular
diseases. In 1993 alone,
genes responsible for a num-





in the film Lorenzo's Oi
Lou Gehrig's disease; and
Huntington's disease. In
addition to determining
who is at risk for developing
heritable diseases, reseach-
ers hope the project will lead
to detect risk of genetic d
exposure to chemicals and
basis for individual susceptible
age as a result of suc exposul
A New Set of Goals
Recognizing that advances :i
have put the Human Genon
or even ahead ofschedule in
Environmental Health Perspectives 54the rate atwhich DNAmaybe sequenced
won't be sufficient for sequencing the
whole genome. The new goal is to
increase sequencing capability (to a rate
of 50 megabases per year by the end of
the period) by increasing the number of
research groups oriented to large-scale
production sequencing. Collins calls for
an immediate investment of$ 00 million
to develop efficient approaches to se-
quencing one to several megabase regions
of DNA of high biological interest, to
develop technology for high through-put
sequencing; and to build up the sequenc-
ing capacity by sequencing the standard
model organisms (mouse, yeast, E. coli, C
elegant, and S. cerevsae) by 1998.
Gene identification. The goal of
* .n . > *o ~~. . I gene identification wasn't specified origi-
nally, although it certainly formed an
implicit element of the project. It is an
area made feasible by progress in map-
ping and development of technologies.
The new goal involves developing effi-
cient methods for identifying and placing
genes on physical maps or sequenced
DNA.
Technology development. Tech-
nology development in all areas, particu-
larlythose such as automation and robot-
ics, is vital to the completion and success
ofthe project and has so far been insuffi-
ciendy funded. In general, the goal is to
substantially expand technological devel-
opments to meet the needs ofthe Human
Genome Project as awhole.
Informaties. The rapid growth of
information on genome mapping and
sequencing make computer-based data
management systems increasingly impor-
tant. The major goal is to create technol-
ogy that will be available to researchers
across the board. Here, too, the project's
original goals are being met with some
efficiency. Several NCHGR- and DOE-
supported databases are available to the
research community, either at no cost or
for the cost of a telephone call to access
them. The Genome Data Base at Johns
Hopkins University is the main public
facility, with approximately 4000 regis-
tered users. It contains information on
maps, polymorphisms, and probes. Other
databases either in operation or under
development will provide access to infor-
mation on the mouse, Drosophila, and
yeast genomes. The expanded goals are to
continue creating the algorithms, sof-
ware, databases, and tools to facilitate
access to the information exchange and
expand the ability to compare and inter-
pret information.
Model organisms. Progress is being
made in sequencing model organisms and
is expected to exceed original goals. The
expanded goals involve finishing a high
resolution STS map ofthe mouse genome
and to continue or finish sequencing E.
Cali, S. cerevisiae, C. elegant, and Drosophila
genomes. Emphasis will be on sequencing
selected areas ofmouse DNA ofhigh bio-
logical interest side by side with corre-
spondinghuman DNA.
Training. The original training goal
was to eventually support 600 pre- and
postdoctoral trainees a year in programs to
take advantage ofthe knowledge generated
by the Human Genome Project such as
clinical applications and applications to
basic research. That turned out to be unre-
alistic, largely because of the inability to
train so many people in the relevant inter-
disciplinary sciences. But now that there
are more genome centers, training oppor-
tunities should expand. The revised goal
encourages training, but doesn't specify a
certain numberoftrainees.
Technology transfer. One ofthe orig-
inal assumptions under which the project
has consistently worked is that knowledge
will be made available, not only to govern-
ment and academic scientists, but to the
private sector, including physicians and
members of private industry. Both the
NIH and DOE genome programs are
required to share information with the pri-
vate sector. Newdataand materials have to
be released within six months oftheir cre-
ation by submitting the information to
public databases and repositories. in prac-
tice, much ofthe new information is dis-
seminated before the 6-month deadline.
The mutual exchange of technology
increases the flow ofinformation from the
genome centers and brings relevant teh-
nologies from other fields in. This practice
is again encouraged inthe new g .
Ethiah egal andsocial i
(ES In the first setofgoals four area
were identified by ELSI advisors for
emphasis: privacy ofgenetic information,
safe and effective introduction, of genetic
information into the clinical setting, fat-i
ness in the use ofgenetic information, and
professional and public education. The
expanded goals recognize the ever-increas-
ing need for strong public policies based
on sound science to deal with the issues
that develop as a resultofthe project. New
goals include continuing to identify,
define, and develop policies to address
issues, developinganddisseminating policy
options regarding genetic testing and ser-
vices, fostering greater understanding and
acceptance of human genetic variation,
and expanding public and professional
education sensitive to sociocultural and
psychological issues.
Outreach. An original goal of the
program that continues to be essential to
its success is to make available to the
community the products of the Human
Genome Project, in all its forms. The
new goals expand outreach goals by en-
couraging flexible distribution systems,
potentially developed through the private
sector, and rules for information sharing
that promote prompt delivery within six
months ofdevelopment.
Money Crunch
The Human Genome Project takes its
funding from both NIH and DOE. But
the goals are extremely ambitious and
expensive, and NIH funds areincreasingly
tight. Originally, a committee of the
National Research Council predicted that
the program would cost about $3 billion
over its 15-year life span, or about $200
million a year. The rosy estimates have
suffered in the budget crunch; today,
when even the mostpopular programs are
taking budget cuts, the genome project's
$165 million ayear seems relatively gener-
ous. Adjusted for inflation, though, that
comes to about 75% of what NRC pre-
dicted the program should cost. As a
result, the priority had to go to gene map-
ping; sequencing and otherequally impor-
tant facets ofthe programhavesuffered.
There is no guarantee that the next
couple of years will be any easier. The
new plan calls for $100 million a year
devoted entirely to sequencing technolo-
gies, which would raise the total to the
ornal $200 million. A 1991 projection
of needs for the program increased its
estmation of the yearly amount needed
by 1994 and 1995 to close to $250 mil-
lion. If the money doesn't come
through, Collins predicts that the
timetable won't be met; that would
mean delayed medical benefits and,
equally important, a loss ofU.S compet-
itveness in biotechnology. Even if
enou money is forthcoming, it may be
hard to meet the sequencing goal. The
program expected that researchers woud
be able to fund new approaches to
sequencing, like mass spectrometry or
atomic force microscopy. Instead, they
will have to try to improve the technolo-
gies that already exist and do as much
cost cutting as possible while trying to
meet the program's goals. Still, Collins
and Galas argue that the genome project
has already had a profound influence on
biomedical research and say they expect
excitingdiscoveries in the years ahead.
Marion Zeiger
Marion Zeiger is a freelance writer in Durham,
North Carolina.
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MSH2, located on chromosome 2, is a flaw
in the system of DNA repair and creates
oncogenes. A normal copy ofthe gene pro-
duces a protein that corrects for errors in
DNA during replication. MSH2 lacks this
ability and allows random mutations to
accumulate in cells, which eventually acti-
vate enough oncogenes to produce a
tumor.
Colon and rectal cancer strike about
158,000 people in the United States each
year, killing 60,000. Scientists estimate
that people who carry the gene have an
80-90% risk ofdeveloping colon or rectal
cancer and a 60-85% chance of develop-
ing cancer of the uterus or ovaries. With
knowledge that they carry the gene, how-
ever, individuals can take preventive steps
such as changing their diet and having fre-
quent examinations. Says Frances Collins,
director of the NCGHR, "For most peo-
ple, knowing you have this gene will prob-
ably save your life."
The Search for Cancer-
Causing Genes
Just as archaeologists study excavated arti-
facts to understand the origins and declines
ofancient civilizations, Curtis C. Harris and
co-workers at the National Cancer Institute
are conducting "molecular archaeology" to
identify the sources and types of alterations
in genes that play a key role in the onset of
many cancers. Says Harris, "Differences in
patterns from one tissue type to another are
clues to etiological factors that are mecha-
nisms of genetic change." It is
important to determine if
these molecular changes are
inherited or a consequence of
exposure to environmental
agents.
Although there are multi-
ple types of cancers in differ-
ent tissues and organs, the
discovery that there is a single
gene that plays an important
role in a wide variety of
tumors was surprising to sci-
entists. The most common
cancer-related genetic change
is in the p53 tumor-suppres- Curtis Harri
sor gene. Harris's work has molecular
revealed a spectrum of muta- change.
tions in the p53 gene associated with a
variety oftumors. The p53 gene encodes a
pleiotropic nuclear phosphoprotein, i.e.,
one that is involved in many functions
including cell cycle control, DNA repair,
DNA synthesis, and cell differentiation.
The positions of tumor mutations in the
p53 gene sequence correlate with regions
of the p53 protein that are important for
its biological activities. A single base substi-
Bermuda triangle? Disease is a result ofthe interaction between genes, age, and the environment.
is-
cluE
tution can result in loss offunction or pro-
duction of this protein essential to tumor
suppression. Endogenous and exogenous
mutagens generate specific kinds of base
substitutions at preferred sites. There are
exceptionally high numbers of mutations
clustered within certain regions of a gene,
creating mutational "hotspots" within this
gene. Different types of cancer, including
colon, lung, liver, and breast cancers, lym-
phomas, and leukemias, are associated with
specific mutational hotspots.
A significant finding of Harris's study
of the p53 gene is that certain mutations
correlate with precise exposure to carcino-
gens. In areas ofChina and southern Africa
where people are exposed
to aflatoxin and hepatitis B
_ virus, there is a high inci-
c dence of liver cancer. Ap-
Q- plying the technology of
° polymerase chain reaction
_ to amplify DNA from liver
tissue samples of cancer
patients and then sequenc-
ing the DNA led to the
discovery that the majority
of cancer patients have a
high frequency of a single
point mutation at codon
249 ofthe p53 tumor-sup-
-Searching for pressor gene. Using poly-
es to genetic merase chain reaction and
sequencing DNA from
healthy tissue from these same patients, it
was determined the mutation was not
inherited; it was a direct result ofexposure
to aflatoxin. This work shows that muta-
tions that confer a selective growth advan-
tage to cells occur nonrandomly and pro-
duce characteristic fingerprints of modifi-
cations in DNA. Harris's examination of
the broad range ofp53 mutations in differ-
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ent tumors is shedding light on environ-
mental and/or endogenous processes that
contribute to carcinogenesis.
Human Genome Project promises to
shed new light on the human genetic code
and the mechanisms by which changes in
that code produce biological effects that
contribute to the complex etiologies of
many cancers. This new knowledge will
generate novel approaches to diagnosis and
treatment ofdisease. Therapies will include
gene replacement, development of drugs
that mimic defective proteins, immunolo-
gy strategies employing serum antibodies,
and development of cancer vaccines. With
better methods for phenotyping and geno-
typing individuals, it will be possible to
develop cancer risk profiles for any individ-
ual within the next 10 years. Such informa-
tion will not only strengthen quantitative
risk assessment, it will provide valuable data
for determining susceptibility and focusing
on appropriate chemopreventive strategies.
With the knowledge that individuals
vary greatly in their response to xenobiotic
exposure, the basic assumption that all
people respond equally to environmental
chemicals, the heretofore modus operandi
of risk assessment, needs to be refined. By
using knowledge gained from molecular
epidemiology about the interaction of
environmental exposure and the suscepti-
bility of individuals to predict biological
effect, the accuracy of risk assessment can
be improved and methods of prevention
for targeted individuals can be prescribed.
As advances in biomarker research contin-
ue, developments in this field will have a
dramatic impact on environmental and
public health policies and will stimulate
debate on controversial ethical issues in the
years to come.
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